Articles tagged with Cancer Patients
The ECOG-ACRIN Cancer Research Group presented promising trial results at ASCO 2022, including an 8-year survival rate in the CHAARTED prostate trial. The research also explored outcomes by tobacco use in head and neck studies, shedding light on cancer treatment effectiveness.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Kaiser Permanente researchers present 10 studies on improving cancer care delivery, including strategies to reduce hospitalizations and mortality among older patients. The studies also explore the use of real-world data versus clinical trials in cancer treatment.
Research suggests that NF-κB over-activation is associated with improved outcomes in patients with HPV-positive head and neck cancer. An RNA-based classifier trained on tumors with specific mutations may improve prognostic classification, aiding in treatment personalization.
Research found that hypomethylating agents (HMAs) activated the oncofetal protein SALL4 in up to 40% of patients with MDS, resulting in poor patient survival. This activation is linked to demethylation and upregulation of oncogenes, suggesting a need for additional combination therapy.
A landmark trial found that a widely used diabetes drug, metformin, is not effective against the most common forms of early-stage breast cancer. However, researchers discovered a potential benefit for individuals with HER2-positive breast cancer, which accounts for about 20% of all breast cancers.
The Sheri and Les Biller Family Foundation has donated $10 million to City of Hope to expand its supportive care programs for cancer patients, improving treatment outcomes and quality of life. The partnership aims to establish supportive care as a standard practice in cancer care across the US.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
A recent study found that nearly one-quarter of young sarcoma patients continue to use opioids after treatment is completed. The researchers highlight the need for monitoring and age-appropriate strategies to manage pain while minimizing opioid exposure.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A new study found that patient-reported physical well-being is a significant factor in determining cancer prognosis and survival. The research highlights the importance of shared decision-making in cancer treatment, suggesting that clinicians should prioritize listening to patients' perspectives.
A new study applies 'Deep Visual Proteomics' to cancer cells, revealing mechanisms driving tumor development and exposing therapeutic targets. The method integrates advances from four technologies to analyze protein landscapes, providing insights into cancer vulnerabilities.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Cancer death rates among Black people decreased steadily between 1999 and 2019, yet they remained significantly higher compared to other racial and ethnic groups. The study highlights the need for improved access to cancer screening, earlier detection, and quality care, as systemic barriers contribute to disparities in cancer outcomes.
A nationwide study of 100 million hospitalizations found that percutaneous coronary intervention is safe and increasing among cancer patients. The study suggests that PCI can nearly double from 2016 to 2018 among patients with thrombocytopenia, without significantly increasing mortality.
Researchers identified two novel biomarkers that predict response to immunotherapy and adverse events in liver cancer patients. The study's findings enable more effective and individualized treatment of primary liver cancer hepatocellular carcinoma (HCC) patients, with fewer side effects.
A new study has found that robotic surgery reduces the chance of readmission by half and reveals a four-fold reduction in blood clots compared to open surgery. Patients also experience increased physical activity, stamina, and quality of life.
A new study reveals massive variations in hospice medication prescriptions, with treatment agency being the primary factor. Patients in agencies with high prescription rates were up to 50 times more likely to receive benzodiazepines or antipsychotics.
Research by University of Texas M.D. Anderson Cancer Center reveals adolescent and young adult leukemia survivors have shorter life spans than those without cancer. The study found inferior long-term mortality outcomes persist even decades after treatment, impacting quality of life and overall survival.
A study published by Mayo Clinic Cancer Center investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with CAR-T cell therapy. The team found that a gene called TIGIT drives CAR-T cell exhaustion and dysfunction, suggesting its blocking strategy may improve treatment efficacy.
A significant proportion of patients with head and neck squamous cell carcinoma who smoke daily at diagnosis continue to smoke two years post-treatment. Most quitters stop smoking within the first six months after treatment.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) found that incorporating the Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) program into electronic health records can significantly improve smoking cessation rates among cancer patients. The research demonst...
A new smoking-cessation program that targets cancer patients has been shown to increase the percentage of patients receiving treatment from 2% to nearly 30%, as well as improve quit rates. The program's costs are also lower than previous methods, averaging $70 per patient.
The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
A systematic review and meta-analysis of 81 studies found that COVID-19 patients with cancer had a higher risk of death compared to those without cancer. Younger age, lung, and hematologic cancers were identified as risk factors for poor outcomes from COVID-19
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Cancer incidence is projected to double in SSA by 2040, with 1.4 million cases per year expected without rapid interventions. Women are more affected by cancer than men in the region, with breast and cervical cancers among the most common types.
CHOP researchers developed CancerVar, an artificial intelligence-empowered platform for interpreting somatic cancer mutations. The tool provides standardized procedures for assessing the clinical impacts of over 13 million somatic cancer mutations.
A recent study in JAMA Otolaryngology–Head & Neck Surgery reveals that thyroid cancer patients in the US experience substantial financial burdens. The researchers propose a novel framework to help guide future research and inform cancer care providers on cost considerations.
A new study uses artificial intelligence to predict bone fractures in cancer patients by creating a digital twin of the vertebra. The AI-assisted framework, ReconGAN, simulates how tumors affect the spine and predicts fracture risks, offering medical experts better treatment strategies and patient decisions.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
A new study led by UTHealth Houston found that patients with recent cancer diagnoses had a higher risk of death and hospitalization, but those with cancer more than one year ago were not significantly associated with increased mortality. The research also confirmed racial disparities in COVID-19 outcomes among cancer patients.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
A study by University of Colorado Cancer Center member Jennifer Raybin found that creative arts therapy significantly improves quality of life for children and adolescents with cancer. The therapy, conducted by a trained clinician, helps patients express and process emotions through activities like dance, yoga, and art-making.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
Researchers found that cancer patients who underwent elective AAA repair were associated with longer hospital stays, renal failure, respiratory problems, and infection. However, a cancer diagnosis did not increase the risk of in-hospital mortality or cardiac complications.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
A recent study found that black patients were significantly less likely to receive proton beam therapy for cancer compared to white patients. The study, which included over 5.2 million patients, also highlighted disparities in treatment based on racial background.
A new study indicates that artificial intelligence can accurately predict who will develop pancreatic cancer based on pre-diagnostic CT scan images. The AI tool was trained to analyze textural differences in the pancreas and achieved an accuracy rate of 86% in identifying those who would eventually develop the disease.
A new study suggests that while breast density knowledge may be increasing due to existing state laws, there is still room for improvement. The study found that most women with non-dense breasts did not correctly know their own density, and that lower education was associated with a lower chance of accurately knowing one's own density.
Researchers developed an AI system using swarm learning to predict cancer from medical images of tissue samples without accessing patient data. The technique improved the detection of genetic changes in colon tumors with high accuracy.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers developed a blood test to detect circulating melanoma cells, which can help diagnose skin cancer and monitor treatment response. The test uses the Melanoma-specific OncoBean platform conjugated with melanoma-specific antibodies.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A study demonstrated that red blood cell vesicles can effectively carry immunotherapeutic RNA molecules to target breast cancer cells. This technology shows promise for delivering therapeutic RNA molecules to disease sites without degradation.
A recent study by Cathy Bradley found that Medicaid patients with continuous coverage have better cancer survival rates compared to those without. Conversely, screening programs for low-income women may not be as effective as general insurance coverage.
Researchers found that low-density neutrophils are associated with chronic inflammation in obesity, which can lead to comorbidities like type 2 diabetes and cancer. Bariatric surgery reduces these cells in circulation, improving metabolic syndrome components.
Researchers at Rutgers University found disparities in palliative care and hospice referrals among minority patient groups, highlighting the need for standardized policies to improve access. The studies revealed that language barriers, economic status, and cultural differences contribute to these gaps in care.
A retrospective study found that higher coronary artery calcium score, higher pulmonary artery-to-aorta ratio, and lower thoracic skeletal muscle index independently predicted worse overall survival. The PA-to-aorta ratio was the most important predictor of overall survival.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
Researchers discovered a link between non-O blood types and an increased risk of developing venous thromboembolism in cancer patients. This finding suggests that blood typing may serve as another important predictive measure for identifying individuals at high risk.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
A new peptide-based vaccine, CoVac-1, has been shown to induce a T cell-dependent response in 93% of patients with B-cell deficiencies, including those with leukemia and lymphoma. The vaccine's T cell immunity exceeds that of individuals without immune deficiency or those who have received standard COVID-19 vaccines.
A recent study found that the Omicron variant is associated with a significant increase in breakthrough infections among cancer patients, especially those undergoing treatment. Protective measures and vaccine adaptations are crucial to mitigate this risk.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
Pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries during the COVID-19 pandemic. The study found that patients in LMICs had 35.7 times the risk of all-cause mortality compared to those in HICs.